SCIENCE
The NOVVA™ Platform
NOVVA™ (Nanocomplex Optimized Vehicle Vectored by Antibody) uses precision-engineered nanocomplexes that deliver powerful drugs directly into tumor cells.
Where antibody-drug conjugates (ADCs) carry only a few toxin molecules, each NOVVA™ nanocomplex carries over a thousand, enabling deeper tumor penetration, sustained local exposure, and reduced systemic toxicity.
By combining proven antibody targets with a modular nanocomplex platform, NOVVA™ transforms how drugs reach solid tumors shielded by biologic barriers.
| NOVVA™ | Antibody Drug Conjugates (ADCs) | Lipid Nanoparticle (LP) Platforms | |
|---|---|---|---|
| Precision targeting | |||
| Deep penetration into dense tumors | |||
| Drug delivery to brain tumors | |||
| Higher payload delivery in tumor | |||
| Minimal off-target exposure |
Publications
A selection of key resources and publications about our pipeline.
➤ Preclinical proof of concept in triple negative breast cancer
➤ Preclinical proof of concept for targeted delivery in glioblastoma
➤ Targeted nanoparticle penetration in glioblastoma
➤ Low-adhesion nanoparticles can solve delivery barrier to reach glioblastoma cells
➤ Fn14 as a therapeutic target across aggressive solid tumors